Wang Xiao, Jin Huali, Du Xiaogang, Cai Chun, Yu Yang, Zhao Gan, Su Baowei, Huang Shan, Hu Yanxin, Luo Dongmei, She Ruiping, Luo Xinsong, Zeng Xianfang, Yi Xinyuan, Wang Bin
State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, 2 Yuanmingyuan Xi Road, Beijing 100094, China.
Vaccine. 2008 Mar 28;26(15):1832-45. doi: 10.1016/j.vaccine.2008.01.056. Epub 2008 Feb 22.
Levamisole (LMS) as an adjuvant enhances cell-mediated immunity in DNA vaccination; we investigated the efficacy and liver immunopathology alleviation of a DNA vaccine, VR1012-SjGST-32, in a LMS formulation in the murine challenge model. Compared to controls, the VR1012-SjGST-32 plus LMS can reduce worm and egg burdens, as well as, immunopathological complications associated chronic inflammation significantly in liver, which were apparently associated with Th1-type response. Together, these results suggest that the LMS as a potential Schistosome DNA vaccine adjuvant can enhance both worm killing and disease prevention, which is possibly mediated through the induction of a strong Th1-dominant environment in immunized mice.
左旋咪唑（LMS）作为佐剂可增强DNA疫苗接种中的细胞介导免疫；我们在小鼠攻击模型中研究了LMS制剂中DNA疫苗VR1012-SjGST-32的疗效和肝脏免疫病理学缓解情况。与对照组相比，VR1012-SjGST-32加LMS可显著降低虫体和虫卵负荷，以及与肝脏慢性炎症相关的免疫病理并发症，这显然与Th1型反应有关。总之，这些结果表明，LMS作为一种潜在的血吸虫DNA疫苗佐剂，可增强杀虫和疾病预防能力，这可能是通过在免疫小鼠中诱导强烈的以Th1为主导的环境来介导的。
